WIDE MOAT STOCKS COMPARISON

Checking

 

Stock Comparison

Merck & Co., Inc. vs Novartis AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Merck & Co., Inc.

MRK · New York Stock Exchange

Market cap (USD)$350.2B
Gross margin (TTM)73%
Operating margin (TTM)9.6%
Net margin (TTM)4.8%
SectorHealthcare
IndustryPharmaceuticals
CountryUS
Data as of2026-08-23
83/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Merck & Co., Inc.'s moat claims, evidence, and risks.

View MRK analysis

Novartis AG

NOVN · SIX Swiss Exchange

Market cap (USD)$272B
Gross margin (TTM)74.7%
Operating margin (TTM)30.2%
Net margin (TTM)22.5%
SectorHealthcare
IndustryPharmaceuticals
CountryCH
Data as of2026-08-23
56/100
Moat score

Weighted across the company's segments.

Full stock profile

Dive deeper into Novartis AG's moat claims, evidence, and risks.

View NOVN analysis

Comparison highlights

  • Moat score gap: Merck & Co., Inc. leads (83 / 100 vs 56 / 100 for Novartis AG).
  • Segment focus: Merck & Co., Inc. has 2 segments (89.4% in Pharmaceutical); Novartis AG has 5 segments (31% in Oncology).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
  • Moat breadth: Merck & Co., Inc. has 3 moat types across 3 domains; Novartis AG has 2 across 2.

Primary market context

Merck & Co., Inc.

Pharmaceutical

Market

Branded prescription pharmaceuticals & human vaccines

Geography

Global

Customer

Wholesalers/retailers, managed care and government payers, hospitals/clinics

Role

R&D-intensive innovator, manufacturer, and marketer

Revenue share

89.4%

Novartis AG

Oncology

Market

Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)

Geography

Global

Customer

Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels

Role

Originator developer, manufacturer, and marketer of oncology therapies

Revenue share

31%

Side-by-side metrics

Merck & Co., Inc.
Novartis AG
Ticker / Exchange
MRK - New York Stock Exchange
NOVN - SIX Swiss Exchange
Market cap (USD)
$350.2B
$272B
Gross margin (TTM)
73%
74.7%
Operating margin (TTM)
9.6%
30.2%
Net margin (TTM)
4.8%
22.5%
Sector
Healthcare
Healthcare
Industry
Pharmaceuticals
Pharmaceuticals
HQ country
US
CH
Primary segment
Pharmaceutical
Oncology
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
83 / 100
56 / 100
Moat domains
Legal, Supply, Demand
Legal, Supply
Last update
2026-09-05
2026-09-05

Moat coverage

Shared moat types

IP Choke Point

Merck & Co., Inc. strengths

Scope EconomiesData Workflow Lockin

Novartis AG strengths

Capex Knowhow Scale

Segment mix

Merck & Co., Inc. segments

Full profile >

Pharmaceutical

Competitive

89.4%

Animal Health

Oligopoly

9.8%

Novartis AG segments

Full profile >

Cardiovascular, Renal and Metabolic

Oligopoly

12.6%

Immunology

Oligopoly

19.1%

Neuroscience

Oligopoly

12.5%

Oncology

Oligopoly

31%

Established Brands

Competitive

24.9%

Act on this comparison

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.